Takeda/Amylin's Pramlintide/Metreleptin Combo Becomes The Latest Obesity Casualty
This article was originally published in PharmAsia News
Executive Summary
Development of a once-promising combination of pramlintide and metreleptin for obesity has been discontinued after a "commercial reassessment," U.S.-based Amylin Pharmaceuticals Inc. and Japan's Takeda Pharmaceutical Company Limited announced Aug. 4
You may also be interested in...
Obesity Drug Developers Go With The Gut: R&D Hopes Focus On Locally Acting Agents
Developers remaining in the daunting weight loss space are pinning their hopes on a new wave of locally acting drugs with the hope that gut-selective mechanisms will show better efficacy combined with fewer safety concerns than the three centrally acting obesity candidates recently rebuffed by FDA.
More Obesity Setbacks For Amylin And Takeda
Neither Amylin Pharmaceuticals Inc. nor its Japanese partner Takeda Pharmaceutical Company Limited has had an easy time of late with diabetes and obesity R&D, and the hold on development for their joint obesity combination therapy shows prospects aren't improving for the firms or the field